Literature DB >> 2182386

Hyperproduction of TEM-1 beta-lactamase in clinical isolates of Escherichia coli serotype O15.

K Shannon1, H Williams, A King, I Phillips.   

Abstract

During an outbreak of infection with ampicillin-resistant, TEM-1 beta-lactamase-producing Escherichia coli serotype O15, some strains were noted to differ from the majority in that they showed reduced susceptibility to amoxycillin/clavulanic acid (Augmentin), ureidopenicillins and first generation cephalosporins and produced increased amounts of beta-lactamase. The plasmid from one such isolate was compared with that from an isolate that produced normal amounts of beta-lactamase. Restriction analysis with EcoRI revealed extra fragments in the plasmid from the beta-lactamase hyperproducer and use of DNA-DNA hybridisation with a biotinylated TEM-1 probe showed genetic rearrangement in the beta-lactamase hyperproducer so that the TEM gene appeared to be present in larger amounts and was located on a smaller fragment than for the plasmid from the strain that produced normal amounts of beta-lactamase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2182386     DOI: 10.1016/0378-1097(90)90016-j

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  13 in total

1.  High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae.

Authors:  L B Rice; L L Carias; A M Hujer; M Bonafede; R Hutton; C Hoyen; R A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Discriminatory detection of inhibitor-resistant beta-lactamases in Escherichia coli by single-strand conformation polymorphism-PCR.

Authors:  V Speldooren; B Heym; R Labia; M H Nicolas-Chanoine
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics.

Authors:  P J Wu; K Shannon; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

4.  Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.

Authors:  P Stapleton; P J Wu; A King; K Shannon; G French; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

Review 5.  Non-canonical mechanisms of antibiotic resistance.

Authors:  J L Martínez; J Blázquez; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-12       Impact factor: 3.267

6.  Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.

Authors:  X Y Zhou; F Bordon; D Sirot; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

7.  Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase.

Authors:  G L French; K P Shannon; N Simmons
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

8.  Molecular epidemiology of the plasmid-encoded TEM-1 beta-lactamase in Scotland.

Authors:  C J Thomson; S G Amyes
Journal:  Epidemiol Infect       Date:  1993-02       Impact factor: 2.451

9.  A strategy design based on antibiotic‑resistance and plasmid replicons genes of clinical Escherichia coli strains.

Authors:  Junyan Liu; Xin Lin; Thanapop Soteyome; Yanrui Ye; Dingqiang Chen; Ling Yang; Zhenbo Xu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

10.  Detection of OXA-1 β-lactamase gene of Klebsiella pneumoniae from blood stream infections (BSI) by conventional PCR and in-silico analysis to understand the mechanism of OXA mediated resistance.

Authors:  Madhan Sugumar; K M Kumar; Anand Manoharan; Anand Anbarasu; Sudha Ramaiah
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.